Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Shire Board of Directors

Matthew Emmens
Chairman

Appointed: March 12, 2003
Committee Membership: Nomination Committee

Matthew served as Shire’s Chief Executive Officer prior to his
appointment as Chairman on June 18, 2008.

Matthew Emmens

Skills & Experience: With 40 years of pharmaceutical experience Matthew contributes a wealth of strategic and operational knowledge to the Company. He began his career in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide range of sales, marketing and administrative positions. In 1992 Matthew helped to establish Astra Merck, Inc., a joint venture between Merck and Astra AB of Sweden, becoming President and Chief Executive Officer. In 1999 he joined Merck KGaA and established EMD Pharmaceuticals, the company’s US prescription pharmaceuticals business. He later served as President of Merck KGaA’s global prescription pharmaceuticals business in Germany. Matthew previously served on the Boards of Vertex Pharmaceuticals, Inc. and Incyte Corporation. He holds a degree in Business Management.

Susan Kilsby
Chairman Designate

Appointed: September 1, 2011
Committee Chairmanship: Audit, Compliance & Risk Committee
Committee Membership: Nomination Committee

Susan Kilsby

Skills & Experience: Susan brings to her role her extensive M&A and finance experience having enjoyed a distinguished global career in investment banking. She held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009 and continues in a part-time senior advisory capacity. Susan is also a former Director of Hong Kong listed global skin care company, L’Occitane International S.A. She holds a BA in Economics and a MBA.

External Appointments: BBA Aviation plc (Non-Executive Director), Coca-Cola HBC AG (Non-Executive Director) and Green Mountain Coffee Roasters, Inc. (Non-Executive Director).

Dr. Flemming Ornskov
Chief Executive Officer

Appointed: January 2, 2013
Committee Chairmanship: Executive Committee

Flemming served as Chief Executive Officer Designate prior to his appointment as Chief Executive Officer on April 30, 2013.

Dr. Flemming Ornskov

Skills & Experience: Flemming brings to his role his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG and was Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Speciality Medicine at Bayer. From 2008 to 2010 Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and as President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming held roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. Flemming received his MD from the University of Copenhagen, MBA from INSEAD and Master of Public Health from Harvard University.

David Kappler
Deputy Chairman and
Senior Independent Non-Executive Director

Appointed: April 5, 2004
Committee Chairmanship: Nomination Committee
Committee Membership: Audit, Compliance & Risk Committee

David was appointed Senior Independent Non-Executive Director in July 2007 and Deputy Chairman in June 2008.

David Kappler

Skills & Experience: David brings to the Board his extensive knowledge and experience in financial reporting, risk management and internal financial controls. He was Chairman of Premier Foods plc until 2010 and held directorships at Camelot Group plc and HMV Group plc. David retired from Cadbury Schweppes plc in 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes Group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. David is a Fellow of the Chartered Institute of Management Accountants.

External Appointments: InterContinental Hotels Group plc (Non-Executive Director).

Dominic Blakemore
Non Executive Director

Appointed: January 1, 2014
Committee Membership: Audit, Compliance & Risk Committee

Dominic Blakemore

Skills & Experience: Dominic brings to the Board his strategic and financial experience having held the positions of Chief Financial Officer at Iglo Foods Group and European Finance & Strategy Director, Corporate Finance Director, and Group Financial Controller at Cadbury plc. Earlier in his career Dominic worked at PricewaterhouseCoopers where he advised pharmaceutical sector clients.

External Appointments: Compass Group PLC (Group Finance Director).

William Burns
Non-Executive Director

Appointed: March 15, 2010
Committee Membership: Remuneration Committee,
Nomination Committee and Science & Technology Committee

William Burns

Skills & Experience: William brings to the Board extensive international sales, marketing, integration and operational experience in the pharmaceutical sector. He worked for many years at Roche, holding the position of CEO of their pharmaceuticals division from 2005 to 2009 and serving as a member of the Roche Group Corporate Executive Committee. William holds a BA (Hons).

External Appointments: Masters Pharmaceuticals (Chairman), Biotie Therapies Corp. (Vice Chairman), Mesoblast Limited (Non-Executive Director), Vestergaard Frandsen (Non-Executive Director), Wellcome Trust (Committee Chairman), University of Strathclyde (International Advisory Panel Chairman) and University of Cologne/Bonn Center for Integrated Oncology (Scientific Advisory Board Member).

Dr. Steven Gillis
Non-Executive Director

Appointed: October 1, 2012
Committee Membership: Remuneration Committee and 
Science & Technology Committee

Dr. Steven Gillis

Skills & Experience: Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. Prior to this Steven was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa he was a founder and Director of Immunex Corporation. An immunologist by training, Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his Ph.D. from Dartmouth College.

External Appointments: ARCH Venture Partners (Managing Director) and bluebird bio, Inc. (Non-Executive Director).

Dr. David Ginsburg
Non-Executive Director

Appointed: June 16, 2010
Committee Chairmanship: Science & Technology Committee

Dr. David Ginsburg

Skills & Experience: David brings to the Board his clinical medical background in
internal medicine, hematology-oncology, and medical genetics, as well as his extensive basic biomedical laboratory research expertise. David obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School. David is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.

External Appointments: University of Michigan (James V. Neel Distinguished University Professor of Internal Medicine, Human Genetics and Pediatrics) and Howard Hughes Medical Institute (Investigator).

Anne Minto
Non-Executive Director

Appointed: June 16, 2010
Committee Chairmanship: Remuneration Committee
Committee Membership: Nomination Committee

Anne Minto

Skills & Experience: Anne brings to the Board her extensive legal, commercial and
remuneration experience. She held the position of Group Director, Human Resources
at Centrica plc from 2002 to 2011 and was a member of the Centrica Executive Committee. Her extensive business career includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. She is also a former Director of Northumbrian Water plc and SITA UK. Anne holds a Law degree and a postgraduate diploma in Human Resources, and is also a qualified lawyer. She is also a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds and is a member of the Law Society of Scotland.

External Appointments: Tate & Lyle PLC (Non-Executive Director), ExlService Holdings, Inc. (Non-Executive Director), University of Aberdeen Development Trust (Trustee) and University of Aberdeen Alumni Fund (Patron).

David Stout
Non-Executive Director

Appointed: October 31, 2009
Committee Membership: Audit, Compliance & Risk Committee and Remuneration Committee

David Stout

Skills & Experience: David brings to the Board extensive international sales, marketing, operational and supply chain experience gained in the pharmaceutical sector. David was President, Pharmaceutical Operations at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations from 2003 to 2008. Prior to that he was President of GlaxoSmithKline’s US pharmaceuticals business and before that SmithKline Beecham’s North American pharmaceuticals business. Before joining SmithKline Beecham, David worked for many years at Schering-Plough. He is also a former Director of Allos Therapeutics, Inc. and holds a BA in Biology.

External Appointments: Jabil Circuit, Inc. (Non-Executive Director) and Airgas, Inc.(Non-Executive Director).

Did you know...

We have developed a
version of this web site
that is suitable for your
portable device
.

Our global reach

Our products are marketed in over 50 countries worldwide, and we now have offices in 29 countries. View our interactive map, and learn more
about our global reach.

Our locations